Compare Global Payments Inc (GPN) vs 10X Genomics Inc (TXG) Price & Performance

Global Payments (GPN) trades at $82.77, up 2.08% with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net income margin and ROE. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains strongly bullish with a $102.75 price target.

GPN presents a mixed outlook with strong analyst support and strategic initiatives offset by profitability concerns and rising debt levels. The stock offers 24% upside to consensus targets but faces execution risks in integrating acquisitions and maintaining margin expansion amid competitive pressures in the payments technology sector.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.